血GP73水平在原发性肝癌TACE疗效评价中的作用  

Role of serum GP73 level in the evaluation of TACE efficacy for primary liver cancer

作　　者：李一帆 朱帝文[1] 任伟新[1] 鲍应军 顾俊鹏[1] 张海潇[1] 曹耿飞 阿斯哈尔·哈斯木 纪卫政[1] Li Yifan;Zhu Diwen;Ren Weixin;Bao Yingjun;Gu Junpeng;Zhang Haixiao;Cao Gengfei;Asihaer·Hasimu;Ji Weizheng(Department of Interventional Radiology,the First Affiliated Hospital of Xinjiang Medical University,Urumqi 830011,China)

机构地区：[1]新疆医科大学第一附属医院介入放射科,乌鲁木齐830011

出　　处：《中华肝脏外科手术学电子杂志》2024年第6期825-830,共6页Chinese Journal of Hepatic Surgery(Electronic Edition)

基　　金：国家自然科学基金(82060334);新疆维吾尔自治区自然科学基金重点项目(2021D01D22);新疆维吾尔自治区第二批“天池英才”青年博士引进计划项目

摘　　要：目的分析血高尔基体跨膜糖蛋白73(GP73)在原发性肝癌(肝癌)TACE治疗前后的变化趋势及其与TACE疗效的相关性,探讨血GP73水平在TACE疗效评价中的作用。方法本前瞻性研究对象为2020年9月至2021年5月新疆医科大学第一附属医院行TACE治疗的51例肝癌患者。患者均签署知情同意书,符合医学伦理学规定。其中男45例,女6例;年龄42~86岁,中位年龄61岁。选取50例正常人群作为对照。TACE疗效评价采用修改后实体瘤疗效评价标准(mRECIST),根据疗效将患者分为疗效好组(18例)和疗效差组(33例)。ELISA法检测TACE治疗前1 d及术后1、3、5、7、30 d血GP73水平。患者与正常人群血GP73比较采用t检验,GP73表达对TACE疗效的影响分析采用重复测量资料的广义估计方程,相关性分析采用Pearson和Spearman相关性分析。结果肝癌患者术前血GP73平均表达量为(0.39±0.25)IU/ml,明显高于正常人群的(0.03±0.01)IU/ml(t=10.841,P<0.05)。TACE术后1 d的GP73表达量较术前明显升高,术后3、5、7 d连续下降,且疗效好组术后7 d的GP73表达量均值较术前明显降低,而疗效差组术后7 d的GP73表达量与术前表达量相近。疗效好组术后30 d的GP73表达量均值较术前及术后7 d进一步下降,疗效差组术后30 d的GP73表达量较术前及术后7 d明显升高。TACE疗效与时间存在明显交互效应(F=15.037,P<0.05)。疗效好组与疗效差组术后5、30 d的GP73表达水平差异有统计学意义(t=4.987,26.788;P<0.05)。术前与术后30 d的GP73变化量与TACE疗效之间存在明显负相关关系(r_(s)=-0.687,P<0.05)。术前GP73与肿瘤直径存在明显的正相关关系(r=0.543,P<0.05)。结论肝癌TACE治疗前后GP73水平的变化与TACE疗效具有明显负相关性,术后1个月GP73降低水平越大,疗效越好,GP73具有评价TACE疗效的潜在价值。Objective To analyze the changing trends of serum Golgi protein 73(GP73)before and after TACE for primary liver cancer(PLC)and its correlation with efficacy of TACE,aiming to explore the role of serum GP73 level in the evaluation of efficacy of TACE.Methods In this prospective study,51 patients with PLC who underwent TACE in the First Affiliated Hospital of Xinjiang Medical University from September 2020 to May 2021 were enrolled.The informed consents of all patients were obtained and the local ethical committee approval was received.Among them,45 patients were male and 6 female,aged 42-86 years,with a median age of 61 years.50 healthy subjects were selected as normal controls.The efficacy of TACE was evaluated based on the modified response evaluation criteria in solid tumors(mRECIST).According to efficacy,all patients were divided into the favorable efficacy group(n=18)and poor efficacy group(n=33).Serum GP73 levels 1 d before TACE and 1,3,5,7 and 30 d after TACE were detected by ELISA.Serum GP73 levels between patients and normal controls were compared by t test.The effect of GP73 expression on TACE efficacy was evaluated by generalized estimation equation of repeated measurement data.Correlation analysis was performed by Pearson's and Spearman's correlation analyses.Results The average expression level of GP73 in PLC patients before TACE was(0.39±0.25)IU/ml,significantly higher than(0.03±0.01)IU/ml in normal controls(t=10.841,P<0.05).The expression level of GP73 at 1 d after TACE was significantly higher than preoperative level,which was decreased continuously at 3,5 and 7 d after TACE.In the favorable efficacy group,the average expression level of GP73 at postoperative 7 d was significantly lower compared with preoperative level,whereas the expression level of GP73 at postoperative 7 d was similar to that before TACE in the poor efficacy group.In the favorable efficacy group,the average expression level of GP73 at 30 d after TACE was further decreased compared with those before and 7 d after TACE,whereas t

关 键 词：癌 肝细胞 肝肿瘤 化学栓塞 治疗性 高尔基体跨膜糖蛋白(GP73) 治疗 

分 类 号：R735.7[医药卫生—肿瘤]